Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a minimal difference between its incidence rate and mortality rate. Advances in oncology over the past several decades have dramatically improved the overall survival of patients with multiple cancers due to the implementation of new techniques in early diagnosis, therapeutic drugs, and personalized therapy. However, pancreatic cancers remain recalcitrant, with a 5-year relative survival rate of <9%. The lack of measures for early diagnosis, strong resistance to chemotherapy, ineffective adjuvant chemotherapy and the unavailability of molecularly targeted therapy are responsible for the high mortality rate of this notorious disease. Genetically, PDAC progresses as a complex result of the activation of oncogenes and inactivation of tumor suppressors. Although next-generation sequencing has identified numerous new genetic alterations, their clinical implications remain unknown. Classically, oncogenic mutations in genes such as KRAS and loss-of-function mutations in tumor suppressors, such as TP53 , CDNK2A , DPC4 / SMAD4, and BRCA2 , are frequently observed in PDAC. Currently, research on these key driver genes is still the main focus. Therefore, studies assessing the functions of these genes and their potential clinical implications are of paramount importance. In this review, we summarize the biological function of key driver genes and pharmaceutical targets in PDAC. In addition, we conclude the results of molecularly targeted therapies in clinical trials and discuss how to utilize these genetic alterations in further clinical practice.

Mutations in Tyrosine Kinase and Tyrosine Phosphatase and Their Relevance to the Target Therapy in Hematologic Malignancies

Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Targeting Protein Degradation Pathways in Tumors: Focusing on Their Role in Hematological Malignancies

Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine

Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Protein Kinases as Tumor Biomarkers and Therapeutic Targets

Advances in targeted therapy for acute myeloid leukemia

Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP

TP53 in MDS and AML: Biological and Clinical Advances.

Genetic mutations in chronic myelogenous leukemia: when to check and what to do?

The Role of TP53 in Acute Myeloid Leukemia: Challenges and Opportunities

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

Recent advances in hematopoietic cell kinase in cancer progression: Mechanisms and inhibitors

TP53 signal pathway confers potential therapy target in acute myeloid leukemia

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors

Advances in molecular evaluation of myeloproliferative neoplasms